CD19-targeted chimeric antigen receptor T-cell Clinical Trials

1 actively recruiting trial

Also known as: PL001

Pipeline

Phase 1/2: 1

Top Sponsors

Pell Bio-Med Technology Co., Ltd.1

Indications

Follicular Lymphoma Grade 3A1
Follicular Lymphoma Grade 3B1
Large B-cell Lymphoma1
Primary Mediastinal Large B-Cell Lymphoma1
Diffuse Large B-Cell Lymphoma1

Other1 trial

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.